abstract |
The present disclosure relates to RNAi agents useful in methods of treating BetanENaC-related diseases such as cystic fibrosis, pseudohypoaldosteronism type 1 (PHA1), nLiddle's syndrome, hypertension, alkalosis, hypokalemia, and obesity-associated nhypertension, using a therapeutically effective amount of a RNAi agent to Beta-ENaC. |